New kid on the CAR-T block: Syncona/UCL form Autolus
This article was originally published in Scrip
Investment company Syncona and UCL Business, the technology transfer arm of University College London, have together set up a new player in the CAR-T field, Autolus. Syncona has given the start-up a £30m cash injection to get going.
You may also be interested in...
New strategies to overcome safety, solid tumor and other challenges associated with CAR-T therapies – and some early clinical data for patients treated with Poseida's, Celyad's and Autolus' novel products – were featured at the American Association for Cancer Research (AACR) meeting.
China's WuXi PharmaTech, an R&D technology company serving the pharmaceutical, biotechnology and medical device industries, has announced construction of a new manufacturing facility in Philadelphia, US designed for cell therapy products, including chimeric antigen receptor T-cell (CAR-T) therapies. More manufacturing power is crucial to the success of this burgeoning, high-potential field.
Takeda has managed to persuade NICE, the health technology appraisal institute for England and Wales, to recommend its ulcerative colitis drug Entyvio (vedolizumab) without the restrictions the institute had previously stipulated – as long as the company offers a discount via a patient access scheme.